In the past week, CANF stock has gone down by -0.97%, with a monthly decline of -7.27% and a quarterly plunge of -32.89%. The volatility ratio for the week is 3.75%, and the volatility levels for the last 30 days are 3.82% for Can-Fite Biopharma Ltd ADR The simple moving average for the last 20 days is -4.32% for CANF’s stock, with a simple moving average of -36.78% for the last 200 days.
Is It Worth Investing in Can-Fite Biopharma Ltd ADR (AMEX: CANF) Right Now?
The stock has a 36-month beta value of 1.04. Opinions on the stock are mixed, with 2 analysts rating it as a “buy”, 0 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for CANF is 4.08M, and at present, short sellers hold a 0.72% of that float. On July 04, 2025, the average trading volume of CANF was 215.80K shares.
CANF stock’s latest price update
Can-Fite Biopharma Ltd ADR (AMEX: CANF)’s stock price has dropped by -0.97% in relation to previous closing price of $1.03. Nevertheless, the company has seen a loss of -0.97% in its stock price over the last five trading days. globenewswire.com reported 2025-04-17 that Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that leading Medical Centers in the US are approaching the FDA, asking for compassionate use approval to treat patients with pancreatic carcinoma with the company oncological drug Namodenoson.
Analysts’ Opinion of CANF
Many brokerage firms have already submitted their reports for CANF stocks, with Maxim Group repeating the rating for CANF by listing it as a “Buy”. The predicted price for CANF in the upcoming period, according to Maxim Group is $7 based on the research report published on August 11, 2017 of the previous year 2017.
H.C. Wainwright gave a rating of “Buy” to CANF, setting the target price at $6 in the report published on November 30th of the previous year.
CANF Trading at -5.51% from the 50-Day Moving Average
After a stumble in the market that brought CANF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.25% of loss for the given period.
Volatility was left at 3.82%, however, over the last 30 days, the volatility rate increased by 3.75%, as shares sank -8.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.82% lower at present.
During the last 5 trading sessions, CANF fell by -0.97%, which changed the moving average for the period of 200-days by -57.50% in comparison to the 20-day moving average, which settled at $1.0660. In addition, Can-Fite Biopharma Ltd ADR saw -60.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of Can-Fite Biopharma Ltd ADR, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for CANF
Current profitability levels for the company are sitting at:
- -12.06% for the present operating margin
- 1.0% for the gross margin
The net margin for Can-Fite Biopharma Ltd ADR stands at -11.69%. The total capital return value is set at -1.15%.
Based on Can-Fite Biopharma Ltd ADR (CANF), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -73.43. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -580.71.
Currently, EBITDA for the company is -8.12 million with net debt to EBITDA at 0.58. When we switch over and look at the enterprise to sales, we see a ratio of 14.08.
Conclusion
To sum up, Can-Fite Biopharma Ltd ADR (CANF) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
